Shares of TESARO, Inc. (NASDAQ:TSRO) have received a consensus rating of “Buy” from the twenty-seven ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $174.32.

TSRO has been the subject of several research reports. FBR & Co lowered their price objective on shares of TESARO from $202.00 to $200.00 and set a “mkt perform” rating for the company in a research note on Wednesday, May 10th. Cowen and Company reissued a “hold” rating and set a $145.00 price objective on shares of TESARO in a research note on Thursday, May 11th. Jefferies Group LLC reissued a “hold” rating on shares of TESARO in a research note on Wednesday, May 10th. Cann reissued an “outperform” rating on shares of TESARO in a research note on Wednesday, May 24th. Finally, Oppenheimer Holdings, Inc. initiated coverage on shares of TESARO in a research note on Thursday, May 25th. They set an “outperform” rating and a $183.00 price objective for the company.

In other TESARO news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the transaction, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 34.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock worth $524,643,000 after buying an additional 3,335,611 shares during the last quarter. Janus Henderson Group PLC purchased a new position in TESARO during the second quarter worth $100,301,000. PointState Capital LP purchased a new position in TESARO during the second quarter worth $85,971,000. TIAA CREF Investment Management LLC boosted its position in TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock worth $56,550,000 after buying an additional 230,353 shares during the last quarter. Finally, Pioneer Investment Management Inc. boosted its position in TESARO by 195.6% in the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock worth $44,441,000 after buying an additional 210,273 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/tesaro-inc-tsro-given-consensus-recommendation-of-buy-by-brokerages/1532560.html.

Shares of TESARO (NASDAQ:TSRO) traded up 1.89% during midday trading on Wednesday, hitting $126.58. The company had a trading volume of 770,054 shares. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The company has a 50-day moving average of $123.96 and a 200-day moving average of $146.46. The company’s market capitalization is $6.86 billion.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period in the prior year, the firm earned ($1.28) earnings per share. The firm’s quarterly revenue was down 17.6% on a year-over-year basis. Analysts predict that TESARO will post ($8.67) earnings per share for the current year.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.